Format

Send to

Choose Destination
See comment in PubMed Commons below
Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8.

Challenges and recommendations for early identification of metastatic disease in prostate cancer.

Author information

1
University of Colorado, Denver-Aurora, CO. Electronic address: edc@edavidcrawford.com.
2
Icahn School of Medicine at Mount Sinai, New York, NY.
3
Fred Hutchinson Cancer Research Center, Seattle, WA.
4
University of Colorado School of Medicine, Denver, CO.
5
Durham VA and Duke University, Durham, NC.
6
Memorial Sloan-Kettering Cancer Center, New York, NY.
7
Thomas Jefferson University, Philadelphia, PA.
8
Oncology Consortium, Scottsdale, AZ.
9
Medical University of South Carolina, Charleston, SC.
10
Lancaster Urology, Lancaster, PA.
11
Carolina Urologic Research Center, Myrtle Beach, SC.
12
Yale University Cancer Center, New Haven, CT.

Abstract

Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.

PMID:
24411213
DOI:
10.1016/j.urology.2013.10.026
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center